PEAL Capital Group

What PEAL Capital Group does

PEAL Capital Group is a Europe-based private equity firm founded in 2022 and headquartered in Zug, Switzerland, with operating entities in London and Dublin. The firm is exclusively focused on the longevity and hormone health sectors, deploying $10–50 million equity cheques to acquire controlling stakes in lower-mid-cap businesses across Western Europe, the UK, North America, Australia, and the Middle East. PEAL sources deals entirely off-market through an Executive Network, Medical Panel, and Family Office relationships, and reports a 2.33x Net MOIC, 58 direct investments, and 65+ years of combined team expertise drawn from prior senior roles at Goldman Sachs, JP Morgan, HSBC, Davy Stockbrokers, and Misland Capital.

The firm operates through a holding platform, L&H Healthcare Services Limited, which integrates accredited medical education with clinical care delivery. The portfolio comprises four education businesses (Derma Medical, DermaHub, Newson Education, Apex Longevity Academy), two clinical networks (Newson Clinics for women, Apex Clinics for men), and a consumer digital health platform (Balance+). The integrated model is designed so that training, clinical practice, and patient-facing data reinforce one another, with reach extending to 68 countries for the medical training platform and 28,000+ active patients and 35,000+ medical professionals served.

PEAL generates revenue through two principal mechanics: traditional private equity fund management (capital appreciation via trade sale, secondary, or IPO exits) and, at the portfolio level, a mix of subscription-based digital education (DermaHub priced £895–£2,995 annually), recurring clinical consultation revenue, and digital health subscriptions including Balance+ premium services and the Balance@Work employer channel. Marketing and investor relations are primarily event- and thought-leadership-driven, led by Founder & Managing Partner Karen O'Mahony.

Name

PEAL Capital Group

Legal name

PEAL Capital Group

Website

https://pealcapital.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

PEAL Capital Group is a 2022-founded, Switzerland-headquartered private equity firm exclusively focused on the longevity and hormone health sectors, deploying $10–50 million equity cheques for controlling stakes in lower-mid-cap businesses across Western Europe, the UK, North America, Australia, and the Middle East, operated through its L&H Healthcare platform.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industries

Micro-PE / Lower Middle Market ETA Funds (FSANALAG), SME Term Loans & Growth Capital (FSAKAGAB)

Keywords

• Private equity investments
• Longevity healthcare sector
• Medical education platforms
• Hormone health clinics
• Specialty healthcare buyouts

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Private Equity Fund Management: PEAL Capital generates returns through capital appreciation of portfolio companies, exiting investments via trade sale, secondary, or IPO at favorable valuations. The firm deploys a three-fund strategy spanning the entire supply chain in longevity and hormone sectors.
2. Medical Education Services: The portfolio companies generate revenue through accredited medical training programs, certification courses, and subscription-based continuous professional development (CPD/ACCME-accredited). Derma Medical offers training in aesthetic procedures with course prices ranging from £895 (Pro Package) to £2,995 (Elite Package).
3. Clinical Services Revenue: L&H Clinics and portfolio clinics (Newson Clinics, Apex Clinics) generate revenue through patient consultations, hormone therapy management, and diagnostic testing services. Newson Clinics operates a hybrid model of in-person and virtual consultations.
4. Digital Health Subscriptions: Balance app generates revenue through Balance+ premium services offering enhanced educational content, expert collaborations, and live events. Balance@Work supports employers through workplace hormone health education.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

PEAL Capital Group is a private equity firm that takes controlling stakes in lower-mid-cap businesses across the longevity and hormone health supply chain, deploying equity cheques of $10 million to $50 million. The firm acquires and operates businesses spanning medical training, telemedicine, diagnostics, and specialty-drug distribution, integrated through the L&H Healthcare Services platform which combines accredited medical education with clinical care delivery. Portfolio assets include aesthetic training providers, hormone health clinics, and digital health platforms serving healthcare professionals and patients globally.

Product overview

PEAL Capital Group operates as a unified healthcare platform focused on longevity and hormonal health, combining medical education with clinical care delivery. The core platform is L&H Healthcare Services Limited, which integrates the Global Longevity Academy (providing medical education and certification) with L&H Clinics (operating clinical care networks). The portfolio includes four medical education businesses (Derma Medical, Apex Longevity Academy, Newson Education, and DermaHub), two clinical clinic networks (Newson Clinics focused on menopause/women's health and Apex Clinics focused on men's health/longevity), and Balance+ digital health platform. This integrated ecosystem creates a closed-loop model where data, education, and clinical practice continually reinforce one another, enabling scalable market expansion from training through to patient treatment.

Differentiator

Problem solved

Functional benefit

Brands

• L&H Healthcare Services: Platform entity specializing in longevity and hormonal health, integrating accredited medical education through the Global Longevity Academy with clinical care delivered by L&H Clinics
• Global Longevity Academy
• L&H Clinics

Products and services

• PEAL Capital Private Equity Funds Private equity fund vehicles focused exclusively on the longevity and hormone health sector, providing institutional investors and family offices with exposure to lower-mid-market healthcare buyouts. Fund investments include medical training, telemedicine, diagnostics, and specialty-drug distribution businesses.
• Derma Medical UK-based aesthetics training business delivering clinical training in cosmetic injectables for healthcare professionals, operating training academies across the United Kingdom, United States and Australia.
• DermaHub Subscription-based digital medical education platform extending clinical learning beyond the classroom, offering accredited online education, on-demand courses, expert-led content, and continuous professional development for healthcare professionals in medical aesthetics.
• Apex Longevity Academy Evidence-based longevity medicine education platform providing CPD- and ACCME-accredited eLearning programmes and clinician-led training for doctors and allied health professionals in metabolic health, lifestyle optimisation, performance medicine, healthy ageing, and disease prevention.
• Newson Education Evidence-based menopause and hormonal health education platform providing CPD-accredited courses, expert-led webinars, and research-driven resources for healthcare professionals globally, having trained over 35,000 medical professionals.
• Newson Clinics Menopause and hormone-health clinics providing personalised, evidence-based care through in-person and virtual appointments, serving over 28,000 active patients with approximately 70% patient retention rate.
• Apex Clinics Men's health and longevity clinics providing personalised, clinically-led care combining diagnostics, hormone therapy including testosterone replacement therapy (TRT), metabolic optimisation, mental wellbeing, and chronic disease prevention.
• Balance+ Digital Health Platform Digital hormone health platform providing trusted, evidence-based hormone health information at scale, with personalized education, symptom tracking, clinical guidance, treatment pathways, Balance AI for personalized health guidance, and Balance+ premium services for enhanced content and live events.

Quantifiable outcome

• 2.33x Net MOIC delivered to investors
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Derma Medical (Acquisition)coreStrategic or Co-development Partner · 1 May 2022PEAL Capital acquired a majority shareholding in Derma Medical (Derma Med Ltd), the UK's leading aesthetic training provider. The investment supports international expansion and operational scaling of the business.
• Finanzombudsstelle Schweiz (FINOS)minorOthersPEAL Capital Partners Swiss AG is a registered member of Finanzombudsstelle Schweiz (FINOS), Switzerland's financial ombudsman service. This membership provides dispute resolution services for Swiss financial sector participants.
• 100 Women in FinanceminorOthersPEAL is actively involved in organizations championing women in finance. 100 Women in Finance is a global organization promoting gender diversity in the alternative investments industry.
• Level 20minorOthersPEAL supports Level 20, a nonprofit organization dedicated to improving gender diversity in the private equity industry across Europe.
• Private Equity Women's Network (PEWN)minorOthersPEAL is actively involved in the Private Equity Women's Network, supporting diversity and inclusion within the private equity industry.
• Professional Advisors (PwC, Silicon Valley Bank, Locke Lord, McCann FitzGerald, Waystone, SEI, Ince, Kroll & RWT Growth)minorImplementation/ SI/ Consulting PartnerPEAL engaged multiple professional service firms for the Derma Medical transaction including PwC (advisory), Silicon Valley Bank (financing), Locke Lord and McCann FitzGerald (legal), Waystone and SEI (fund administration), and various other advisors representing vendors.

Scale indicators11 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Ahren Innovation Capital: UK-based venture capital firm investing exclusively in longevity and healthspan-related science and technology. Directly comparable to PEAL as a specialist investor focused on the same longevity/hormone health thesis, albeit at earlier stages and more science-oriented.
• LongeVC: Venture capital firm backing early-stage companies in longevity, biotech and healthspan. Direct peer as a dedicated longevity-sector investor with similar thematic conviction and brand positioning.
• Apollo Health Ventures: Europe-based venture capital firm investing in biotech and healthspan-focused companies targeting the biology of aging. Highly comparable as a longevity-specialist investor with similar thematic focus on healthspan and age-related disease.

Broad incumbents

• EQT Life Sciences: EQT's dedicated healthcare and life sciences private equity platform investing across Europe. Comparable as a healthcare-focused PE firm with strong European footprint and overlapping interest in health-services assets.
• Permira: Global private equity firm with an active healthcare and consumer services franchise. Comparable as a sector-specialist PE firm operating across European mid-market opportunities with overlapping healthcare exposure.
• Bain Capital Life Sciences: Bain Capital's dedicated life sciences and healthcare private equity platform. Comparable in healthcare PE investing, but at much greater scale and broader therapeutic-area coverage than PEAL's single-vertical approach.
• KKR Healthcare Strategic Growth: Growth-stage private equity strategy within KKR focused on healthcare and life sciences. Comparable as a healthcare-focused PE investor, but operates at much larger cheque sizes across a broad healthcare mandate rather than a single vertical.
• TPG Capital Healthcare: TPG's healthcare-focused private equity franchise investing across services, life sciences and healthcare technology. Comparable as a large healthcare PE competitor, but operating a much broader mandate with larger cheque sizes.
• Carlyle Global Healthcare: Carlyle Group's global healthcare private equity franchise investing across pharma, medtech and healthcare services. Comparable as a healthcare-focused PE peer with significantly larger fund size and broader sector coverage.

Emerging players

• Bridgepoint Healthcare: European mid-market private equity firm with an active healthcare services franchise. Comparable as a European mid-market PE peer competing for healthcare assets in similar deal-size range as PEAL.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pealcapitalgroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PEAL Capital Group